** Shares of consumer healthcare co Kenvue KVUE.N fall ~2% to $20.33 premarket
** Co forecasts 2025 adjusted profit below estimates hit by a stronger dollar and weak demand for its cough and cold products
** Co forecasts flat to 2% growth in 2025 adjusted EPS, compared with $1.14 it earned in 2024
** Analysts expect earnings to grow 5.6% this year, or to $1.21 per share, according to estimates compiled by LSEG
** Reports Q4 sales of $3.66 billion slightly missing estimates of $3.77 billion, hit by low incidences of cold, cough and flu
** Stock fell over 20% since its stock market debut in May 2023
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))